CL2017002686A1 - Métodos para tratar o prevenir dolor de cabeza por migraña - Google Patents

Métodos para tratar o prevenir dolor de cabeza por migraña

Info

Publication number
CL2017002686A1
CL2017002686A1 CL2017002686A CL2017002686A CL2017002686A1 CL 2017002686 A1 CL2017002686 A1 CL 2017002686A1 CL 2017002686 A CL2017002686 A CL 2017002686A CL 2017002686 A CL2017002686 A CL 2017002686A CL 2017002686 A1 CL2017002686 A1 CL 2017002686A1
Authority
CL
Chile
Prior art keywords
methods
migraine headache
treat
cgrp receptor
prevent migraine
Prior art date
Application number
CL2017002686A
Other languages
English (en)
Inventor
Hong Sun
Eduardo Dunayevich
Robert A Lenz
Gabriel Vargas
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2017002686A1 publication Critical patent/CL2017002686A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment And Processing Of Natural Fur Or Leather (AREA)

Abstract

<p>La presente invención se refiere a métodos de profilaxis de migraña utilizando anticuerpos anti-receptor CGRP o fragmentos de unión. En particular, se describen los métodos para prevenir o reducir la ocurrencia de dolor de cabeza por migraña en un paciente en necesidad del mismo comprende administrar al paciente un receptor anti-CGRP o fragmento de unión de acuerdo con los regímenes de dosificación específicos. También se describen composiciones farmacéuticas y dispositivos de administración que comprenden anticuerpos anti-receptor CGRP o fragmentos de unión para el uso en los métodos.</p>
CL2017002686A 2015-04-24 2017-10-23 Métodos para tratar o prevenir dolor de cabeza por migraña CL2017002686A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562152708P 2015-04-24 2015-04-24

Publications (1)

Publication Number Publication Date
CL2017002686A1 true CL2017002686A1 (es) 2018-05-11

Family

ID=53969433

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002686A CL2017002686A1 (es) 2015-04-24 2017-10-23 Métodos para tratar o prevenir dolor de cabeza por migraña

Country Status (30)

Country Link
US (3) US10259877B2 (es)
EP (2) EP3653225A1 (es)
JP (4) JP6392471B2 (es)
KR (1) KR102464415B1 (es)
CN (2) CN108156814B (es)
AU (2) AU2015392215B2 (es)
BR (1) BR112017022772A2 (es)
CA (1) CA2984254C (es)
CL (1) CL2017002686A1 (es)
CY (1) CY1123211T1 (es)
DK (1) DK3285803T3 (es)
ES (1) ES2771925T3 (es)
HK (1) HK1250914A1 (es)
HR (1) HRP20200056T1 (es)
HU (1) HUE048528T2 (es)
IL (2) IL255114B (es)
JO (2) JOP20200116A1 (es)
LT (1) LT3285803T (es)
MA (2) MA41932B1 (es)
MX (2) MX2017013627A (es)
PH (1) PH12017501934A1 (es)
PL (1) PL3285803T3 (es)
PT (1) PT3285803T (es)
RS (1) RS59912B1 (es)
RU (1) RU2707745C2 (es)
SG (2) SG10202004282RA (es)
SI (1) SI3285803T1 (es)
TW (2) TWI799849B (es)
WO (1) WO2016171742A1 (es)
ZA (1) ZA201707179B (es)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519224B2 (en) 2014-03-21 2019-12-31 Teva Pharmaceuticals International Gmbh Treating headache comprising administering an antibody to calcitonin gene-related peptide
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US11028160B2 (en) 2016-09-23 2021-06-08 Teva Pharmaceuticals International Gmbh Treating refractory migraine

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
WO2018160897A1 (en) 2017-03-02 2018-09-07 Beth Israel Deaconess Medical Center, Inc. Preventing post-ictal headaches
WO2019055399A1 (en) * 2017-09-12 2019-03-21 Igc Bio, Inc. ANTI-VEGF ANTIBODIES
BR112020013621A2 (pt) 2018-01-12 2020-12-01 Amgen Inc. anticorpos contra pac1 e usos dos mesmos
US11407838B2 (en) * 2018-04-02 2022-08-09 Amgen Inc. Erenumab compositions and uses thereof
EP4302828A3 (en) * 2018-07-05 2024-01-17 Allergan Pharmaceuticals International Limited Combination therapy with cgrp antagonists and clostridial derivatives
JP2022516956A (ja) 2019-01-08 2022-03-03 ハー・ルンドベック・アクチエゼルスカベット 抗ｃｇｒｐ抗体を用いた頭痛の急性治療及び迅速治療
AU2020267107A1 (en) * 2019-05-02 2021-10-07 H. Lundbeck A/S Treatment of headache using anti-CGRP antibodies
US20210121541A1 (en) 2019-07-05 2021-04-29 Allergan Pharmaceuticals International Limited CGRP Antagonists and Clostridial Derivatives for the Treatment of Neuropsychiatric and Neurological Disorders
US20210128724A1 (en) 2019-07-05 2021-05-06 Allergan Pharmaceuticals International Limited Cgrp antagonists and clostridial derivatives for the treatment of cortical spreading depression associated disorders
WO2021005493A1 (en) 2019-07-05 2021-01-14 Allergan Pharmaceuticals International Limited Cgrp antagonists and botulinum toxins for the treatment of inflammatory and neurologic disorders
CA3161376A1 (en) * 2019-12-18 2021-06-24 Anthony P. FORD Methods for improving neurological diseases and disorders
KR20230157986A (ko) 2021-03-02 2023-11-17 체게에르페 다이어그노스틱스 게엠베하 편투통 발생의 치료 및/또는 저감
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
DK0710719T3 (da) 1990-01-12 2007-07-09 Amgen Fremont Inc Frembringelse af xenogene antistoffer
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0590076A4 (en) 1991-06-14 1997-02-12 Dnx Corp Production of human hemoglobin in transgenic pigs
DE69224906T2 (de) 1991-07-08 1998-10-29 Univ Massachusetts Thermotropes flüssig-kristallines segment-blockcopolymer
DE69324579T2 (de) 1992-03-17 1999-09-23 Novartis Ag Gentechnologisch hergestellte antikörper
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
WO1996005221A1 (en) 1994-08-16 1996-02-22 Human Genome Sciences, Inc. Calcitonin receptor
US5785682A (en) 1995-03-22 1998-07-28 Abbott Laboratories Pre-filled syringe drug delivery system
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
AU6596096A (en) 1996-07-23 1998-02-10 Smithkline Beecham Corporation Calcitonin gene-related peptide receptor component factor (houdc44)
US6255455B1 (en) 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
EP0942968B1 (en) 1996-12-03 2008-02-27 Amgen Fremont Inc. Fully human antibodies that bind EGFR
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
FR2821080B1 (fr) 2001-02-20 2003-12-19 Sanofi Synthelabo Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques
EP1438325B1 (en) 2001-09-27 2009-12-30 Merck & Co., Inc. Isolated dna molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
ES2323170T3 (es) 2002-08-12 2009-07-08 Birkir Sveinsson Uso de compuestos antagonistas del cgrp para el tratamiento de la psoriasis.
US20040176577A1 (en) 2002-09-10 2004-09-09 Eva Rojer Immunoassays for specific determination of SCCA isoforms
WO2004097421A2 (en) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
US7569578B2 (en) 2003-12-05 2009-08-04 Bristol-Meyers Squibb Company Heterocyclic anti-migraine agents
KR20120034237A (ko) 2004-02-11 2012-04-10 아밀린 파마슈티칼스, 인크. 선택가능한 특성을 갖는 하이브리드 폴리펩티드
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
EP2284194A1 (en) 2004-12-21 2011-02-16 AstraZeneca AB Antibodies directed to angiopoietin-2 and uses thereof
DE102004063753A1 (de) 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
US9072777B2 (en) 2005-06-16 2015-07-07 Takayuki Shindo Method for screening substance having proangiogenic effect
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
JP5123197B2 (ja) * 2005-11-14 2013-01-16 ライナット ニューロサイエンス コーポレイション カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体およびその使用方法
AU2006316642A1 (en) 2005-11-18 2007-05-31 Merck Sharp & Dohme Corp. Spirolactam tricyclic CGRP receptor antagonists
WO2007076336A1 (en) 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
JP4435288B2 (ja) 2006-05-09 2010-03-17 メルク エンド カムパニー インコーポレーテッド 置換スピロ環ｃｇｒｐ受容体アンタゴニスト
CA2658612C (en) 2006-08-03 2015-11-17 Astrazeneca Ab Antibodies directed to .alpha.v.beta.6 and uses thereof
AU2008239754A1 (en) 2007-04-11 2008-10-23 Merck Sharp & Dohme Corp. CGRP receptor antagonists with tertiary amide, sulfonamide, carbamate and urea end groups
JP2010524934A (ja) 2007-04-16 2010-07-22 メルク・シャープ・エンド・ドーム・コーポレイション アリール複素環式ｃｇｒｐ受容体アンタゴニスト
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
NZ587297A (en) 2008-03-04 2012-10-26 Pfizer Ltd Use of anti-CGRP (calcitonin gene-related peptide) antagonists to treat inflammatory pain
AU2009257733A1 (en) 2008-06-12 2009-12-17 Merck Sharp & Dohme Corp. Branched 3- and 6-substituted quinolines as CGRP receptor antagonists
FR2934597B1 (fr) 2008-07-31 2013-04-19 Univ Aix Marseille Ii Anticorps se liant aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament.
CA2737711A1 (en) 2008-09-18 2010-03-25 Merck Sharp & Dohme Corp. Bicyclic dihydroimidazolone cgrp receptor antagonists
EP2340025B1 (en) 2008-10-03 2014-10-15 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
EP2470207A1 (en) 2009-08-28 2012-07-04 Rinat Neuroscience Corporation Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
AR081434A1 (es) 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
JOP20190250A1 (ar) * 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
CN103702685B (zh) * 2011-05-20 2017-12-15 奥尔德生物控股有限责任公司 抗cgrp抗体和抗体片段用于在有需要的受试者、尤其是偏头痛患者中预防或抑制畏光或厌光的用途
PL2710039T3 (pl) 2011-05-20 2019-07-31 Alderbio Holdings Llc Kompozycje przeciwko CGRP i ich zastosowanie
EP2709662B1 (en) * 2011-05-20 2019-07-31 AlderBio Holdings LLC Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
EA032830B1 (ru) 2013-03-15 2019-07-31 Эмджен Инк. Антитела к pac1 человека и их применение для лечения головной боли
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
CN111973740A (zh) 2014-03-21 2020-11-24 泰华制药国际有限公司 针对降钙素基因相关肽的拮抗剂抗体及其使用方法
MX2017003247A (es) * 2014-09-15 2017-11-30 Amgen Inc Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519224B2 (en) 2014-03-21 2019-12-31 Teva Pharmaceuticals International Gmbh Treating headache comprising administering an antibody to calcitonin gene-related peptide
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US11555064B2 (en) 2014-03-21 2023-01-17 Teva Pharmaceuticals International Gmbh Treating headache comprising administering an antibody to calcitonin gene-related peptide
US11028160B2 (en) 2016-09-23 2021-06-08 Teva Pharmaceuticals International Gmbh Treating refractory migraine
US11028161B2 (en) 2016-09-23 2021-06-08 Teva Pharmaceuticals International Gmbh Treating refractory migraine

Also Published As

Publication number Publication date
JP2018513871A (ja) 2018-05-31
JOP20200116A1 (ar) 2017-06-16
HRP20200056T1 (hr) 2020-04-03
SI3285803T1 (sl) 2020-02-28
MX2017013627A (es) 2018-07-06
BR112017022772A2 (pt) 2018-07-31
US20230020514A1 (en) 2023-01-19
US20160311913A1 (en) 2016-10-27
ES2771925T3 (es) 2020-07-07
AU2015392215A1 (en) 2017-11-09
US20190256607A1 (en) 2019-08-22
PT3285803T (pt) 2020-02-18
RS59912B1 (sr) 2020-03-31
JP6707590B2 (ja) 2020-06-10
KR102464415B1 (ko) 2022-11-04
RU2707745C2 (ru) 2019-11-29
ZA201707179B (en) 2020-01-29
HK1250914A1 (zh) 2019-01-18
EP3653225A1 (en) 2020-05-20
HUE048528T2 (hu) 2020-07-28
TW202130369A (zh) 2021-08-16
AU2022204866A1 (en) 2022-08-18
TWI728953B (zh) 2021-06-01
TWI799849B (zh) 2023-04-21
MA51815A (fr) 2020-12-23
PL3285803T3 (pl) 2020-06-01
DK3285803T3 (da) 2020-02-17
CN113908268A (zh) 2022-01-11
MX2021013327A (es) 2021-11-17
IL255114A0 (en) 2017-12-31
IL291153A (en) 2022-05-01
JP2019001800A (ja) 2019-01-10
TW201637667A (zh) 2016-11-01
CY1123211T1 (el) 2021-12-31
CN108156814B (zh) 2021-07-09
CA2984254A1 (en) 2016-10-27
MA41932B1 (fr) 2020-04-30
JO3559B1 (ar) 2020-07-05
JP2020143115A (ja) 2020-09-10
CN108156814A (zh) 2018-06-12
RU2017140789A (ru) 2019-05-24
US10259877B2 (en) 2019-04-16
RU2017140789A3 (es) 2019-05-24
KR20180002711A (ko) 2018-01-08
SG10202004282RA (en) 2020-06-29
US11466090B2 (en) 2022-10-11
CA2984254C (en) 2019-09-24
PH12017501934A1 (en) 2018-03-19
LT3285803T (lt) 2020-02-10
EP3285803B1 (en) 2019-12-18
JP2022126724A (ja) 2022-08-30
IL291153B2 (en) 2023-06-01
WO2016171742A1 (en) 2016-10-27
IL255114B (en) 2022-04-01
JP6392471B2 (ja) 2018-09-19
SG11201708607WA (en) 2017-11-29
EP3285803A1 (en) 2018-02-28
AU2015392215B2 (en) 2022-04-07

Similar Documents

Publication Publication Date Title
CL2017002686A1 (es) Métodos para tratar o prevenir dolor de cabeza por migraña
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
MX2022003572A (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
CO2019002371A2 (es) Adenovirus armado con captador biespecífico de linfocitos t (bite)
CO2017006580A2 (es) Anticuerpos humanos para hemaglutinina de influenza
CL2017001920A1 (es) Anticuerpos humanos contra glicoproteína del virus ébola
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
BR112018003984A2 (pt) anticorpos
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
EA201692285A1 (ru) Ингибиторы ezh2 для лечения лимфомы
BR112013006395A2 (pt) moduladores do receptor de estrogênio e seus usos.
BR112016002401A8 (pt) Métodos para reduzir as taxas de exacerbação de asma usando benralizumab
NZ761478A (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
UY34116A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
MX2018003713A (es) Prevencion, tratamiento y reduccion del dolor de cabeza postraumatico (persistente).
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
CL2017001756A1 (es) Régimen de dosificación para antagonistas de madcam.
BR112022000581A2 (pt) Métodos para tratamento de alergia e intensificação de imunoterapia específica dos alergénos através da administração de um antagonista de il-4r
BR112021021195A2 (pt) Métodos para tratamento ou prevenção da asma pela administração de um antagonista de il-33
BR112017003332A2 (pt) uso de antagonistas de il-17 para inibir a progressão de dano estrutural em pacientes com artrite psoriásica
UY37449A (es) Anticuerpos anti-chikv y usos de éstos
CL2021001479A1 (es) Péptido; uso de composiciones; composición farmacéutica; uso de un anticuerpo para terapia; uso de un anticuerpo para elisa, inmunohistoquímica y/o formación de imágenes; receptor de linfocito t; y uso de un linfocito t citotóxico activado (divisional de la solicitud n° 201701391)
BR112019011461A2 (pt) terapia celular à base de nk melhorada
EA202190966A1 (ru) Пролекарства антагонистов cgrp
EA201990041A1 (ru) Композиции, содержащие тимолол, и их применение при лечении розацеа при местном применении